Amy McGeoch earned her Bachelor's degree in biochemistry from the University of Leeds. She plans to investigate the involvement of cyclin-dependent kinase complexes in non-canonical pathways such as ...

Victoria Cushing earned her Master's degree in biochemistry from the University of Oxford. She is investigating the structure and function of CAK and is currently pursuing high-resolution structures ...

Lucy Dan earned her Master's degree in biological sciences from Durham University. She is a ICR/Imperial Convergence Science Centre student and will investigate novel ways to target the activities of ...

In 1995, our researchers discovered the cancer gene BRCA2, which, when mutated, can make carriers more likely to develop cancer. This discovery means that families can now assess their cancer risk ...

Karin Manchester, 65, was told she had a week to live after being diagnosed with acute myeloid leukaemia (AML), a type of blood cancer, in 2004. Thanks to successful treatment and taking part in a ...

CRIS Cancer Foundation and the ICR are offering 2-3 year fellowships to support the development of outstanding early ...

The Centre for Molecular Pathology is a collaborative initiative between The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, aiming to identify the molecular mechanisms that ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

The Innovation Gateway is a new high-quality incubator space for life-science companies, at the heart of The London Cancer Hub in Sutton, South London – a partnership led by The Institute of Cancer ...

We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...